接受免疫抑制治疗的免疫介导炎症性疾病患者中标准与第三剂SARS-CoV-2疫苗接种的免疫原性与安全性
这项前瞻性观察研究纳入接受免疫抑制治疗的类风湿关节炎、脊柱关节炎、银屑病关节炎、克罗恩病或溃疡性结肠炎成年患者及健康对照,评估标准两剂SARS-CoV-2疫苗接种后的血清学应答与不良事件。1,505例患者(91%)与1,096例健康对照(98%)产生血清学应答(P<0.001),患者抗RBD抗体水平低于对照。153例弱应答患者接种第三剂后129例(84%)转为应答者,疫苗安全性与对照相当。
要点
- 接受免疫抑制治疗的患者对标准两剂SARS-CoV-2疫苗的血清学应答率(91%)低于健康对照(98%),抗RBD抗体水平也更低。
- 接受TNF抑制剂联合治疗、JAK抑制剂或阿巴西普的患者应答比例最低;年轻年龄和接种mRNA-1273疫苗是血清学应答的预测因素。
- 153例标准方案弱应答者接种第三剂后129例(84%)成为应答者,患者与对照的疫苗安全性特征相当。
核心结论
- 免疫介导炎症性疾病患者对标准SARS-CoV-2疫苗接种方案的应答较健康对照减弱;第三剂疫苗安全,且使多数患者产生血清学应答。
- 这些数据有助于识别疫苗应答减弱风险较高的患者群体,并支持对标准方案血清学弱应答的免疫介导炎症性疾病患者接种第三剂疫苗。
研究设计与样本
- 前瞻性观察研究,纳入接受免疫抑制治疗的风湿关节炎、脊柱关节炎、银屑病关节炎、克罗恩病或溃疡性结肠炎成年患者及健康成年对照,均接受标准两剂SARS-CoV-2疫苗接种方案。
- 在接种前及接种后2-4周检测针对SARS-CoV-2刺突蛋白受体结合域(RBD)的抗体。
- 对全长SARS-CoV-2刺突蛋白受体结合域IgG抗体滴度≤100 AU/ml(定义为弱血清学应答)的患者分配第三剂疫苗。
主要发现
- 1,505例患者(91%)与1,096例健康对照(98%)对标准方案产生血清学应答(P<0.001)。
- 患者抗RBD抗体水平(中位数619 AU/ml,四分位距192-4,191)低于对照(中位数3,355 AU/ml,四分位距896-7,849)(P<0.001)。
- 接受TNF抑制剂联合治疗、JAK抑制剂或阿巴西普的患者应答比例最低;年轻年龄与接种mRNA-1273疫苗是血清学应答的预测因素。
- 153例标准方案弱应答并接种第三剂的患者中,129例(84%)成为应答者;患者与对照的疫苗安全性特征相当。
关键数值与推荐
- 弱血清学应答定义为针对全长SARS-CoV-2刺突蛋白受体结合域的IgG抗体滴度≤100 AU/ml。
- 标准两剂方案后血清学应答率:患者91%(1,505例)vs 健康对照98%(1,096例)(P<0.001)。
- 抗RBD抗体中位数:患者619 AU/ml(IQR 192-4,191)vs 健康对照3,355 AU/ml(IQR 896-7,849)(P<0.001)。
- 第三剂后:153例弱应答患者中129例(84%)成为应答者。
临床怎么用
- 作者认为这些数据有助于识别疫苗应答减弱风险较高的患者群体,并支持对标准方案血清学弱应答的免疫介导炎症性疾病患者接种第三剂疫苗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Immunogenicity and safety following receipt of the standard SARS-CoV-2 vaccination regimen in patients with immune-mediated inflammatory diseases (IMIDs) are poorly characterized, and data after receipt of the third vaccine dose are lacking. The aim of the study was to evaluate serologic responses and adverse events following the standard 2-dose regimen and a third dose of SARS-CoV-2 vaccine in IMID patients receiving immunosuppressive therapy. METHODS: Adult patients receiving immunosuppressive therapy for rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, Crohn's disease, or ulcerative colitis, as well as healthy adult controls, who received the standard 2-dose SARS-CoV-2 vaccination regimen were included in this prospective observational study. Analyses of antibodies to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein were performed prior to and 2-4 weeks after vaccination. Patients with a weak serologic response, defined as an IgG antibody titer of ≤100 arbitrary units per milliliter (AU/ml) against the receptor-binding domain of the full-length SARS-Cov-2 spike protein, were allotted a third vaccine dose. RESULTS: A total of 1,505 patients (91%) and 1,096 healthy controls (98%) had a serologic response to the standard regimen (P < 0.001). Anti-RBD antibody levels were lower in patients (median 619 AU/ml interquartile range [IQR] 192-4,191) than in controls (median 3,355 AU/ml [IQR 896-7,849]) (P < 0.001). The proportion of responders was lowest among patients receiving tumor necrosis factor inhibitor combination therapy, JAK inhibitors, or abatacept. Younger age and receipt of messenger RNA-1273 vaccine were predictors of serologic response. Of 153 patients who had a weak response to the standard regimen and received a third dose, 129 (84%) became responders. The vaccine safety profile among patients and controls was comparable. CONCLUSION: IMID patients had an attenuated response to the standard vaccination regimen as compared to healthy controls. A third vaccine dose was safe and resulted in serologic response in most patients. These data facilitate identification of patient groups at risk of an attenuated vaccine response, and they support administering a third vaccine dose to IMID patients with a weak serologic response to the standard regimen.
引用
- Syversen SW, Jyssum I, Tveter AT, et al. Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy. Arthritis Rheumatol. 2022. PMID: 35507355. doi:10.1002/art.42153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。